Enrique Grande, One Oncology Madrid Program Director at Quironsalud, shared on X:
“CA017-078 (ENERGIZE) ESMO26
Phase 3 trial of neoadjuvant nivolumab + gemcitabine-cisplatin followed by adjuvant nivolumab vs neoadjuvant gemcitabine-cisplatin in cisplatin-eligible MIBC (n=653).
Neither co-primary endpoint was met: EFS HR 0.94; pCR 39.1% vs 29.6% (not statistically significant). Exploratory analyses associated ctDNA detection at baseline and at cycle 4 with shorter EFS and OS.”
Title: Neoadjuvant nivolumab plus gemcitabine–cisplatin followed by postsurgical adjuvant nivolumab versus neoadjuvant gemcitabine–cisplatin in patients with muscle-invasive bladder cancer: final results from the phase III CA017-078 trial
Authors: G. Sonpavde, M.S. van der Heijden, S. Gupta, M.D. Galsky, G. Steinberg, J.E. Gschwend, J.P. Sade, D. Bimbatti, U. De Giorgi, G. Schepisi, S. Vázquez Estévez, S. Panay, G. Schinzari, A. Kotsakis, H. Miyake, J.J. Oh, J. Zhang, C. Jeyamohan, J. Neely, M. Jacques, Q. Duong, S. Sarkar, A. Necchi
You can also read:
GDFATHER-NEO: Neoadjuvant Nivolumab + Visugromab in MIBC
